New data demonstrates nu.q® is effective in monitoring treatment of sepsis

Austin, texas, march 17, 2021 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working with swiss-based santersus ag, a private company that has an abstract released today at the international society for apheresis meeting (e-isfa), which is being held virtually this year. the poster presentation entitled "therapeutic removal of nets from blood in a pig model of sepsis" given by dr. andrew aswani, consultant in intensive care medicine & anesthesia at a leading london hospital and chief medical officer of santersus ag, includes data showing that nu.q® is an effective method for monitoring santersus' highly selective plasmapheresis treatment targeting neutrophil extracellular traps ("nets") in sepsis.
VNRX Ratings Summary
VNRX Quant Ranking